PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1317780-5 1992 In rat anterior pituitary cells cultured in the absence of progesterone, it was found that the progesterone receptor antagonist RU486 (2 nM) inhibits LHRH self-potentiation induced by hourly pulses of 1 nM LHRH. Mifepristone 128-133 progesterone receptor Rattus norvegicus 95-116 1562510-3 1992 Although the roles of progesterone and the progesterone receptor in control of cell growth remain unclear, it was found in progesterone receptor positive mammary carcinoma cell lines that the antiprogestin, Mifepristone, had an inhibitory effect on cell growth and a growth-inhibiting action on the DMBA-induced mammary carcinoma of the rat. Mifepristone 207-219 progesterone receptor Rattus norvegicus 43-64 1562510-3 1992 Although the roles of progesterone and the progesterone receptor in control of cell growth remain unclear, it was found in progesterone receptor positive mammary carcinoma cell lines that the antiprogestin, Mifepristone, had an inhibitory effect on cell growth and a growth-inhibiting action on the DMBA-induced mammary carcinoma of the rat. Mifepristone 207-219 progesterone receptor Rattus norvegicus 123-144 1958508-1 1991 The antiprogestin RU486 has been shown to inhibit the growth of a number of tumor cell lines and solid tumors which contain significant concentrations of progesterone receptor (PgR). Mifepristone 18-23 progesterone receptor Rattus norvegicus 154-175 1958508-1 1991 The antiprogestin RU486 has been shown to inhibit the growth of a number of tumor cell lines and solid tumors which contain significant concentrations of progesterone receptor (PgR). Mifepristone 18-23 progesterone receptor Rattus norvegicus 177-180 1958508-7 1991 RU486 treatment alone suppressed PgR content and resulted in only insignificant inhibition of growth. Mifepristone 0-5 progesterone receptor Rattus norvegicus 33-36 1958508-8 1991 However, when significant PgR concentrations were maintained by combined treatment with DES, RU486 significantly suppressed tumor growth (0.01 less than P less than 0.05 vs controls). Mifepristone 93-98 progesterone receptor Rattus norvegicus 26-29 2156667-14 1990 The progesterone receptor antagonist RU486 administered alone had no effect on serum LH or FSH levels. Mifepristone 37-42 progesterone receptor Rattus norvegicus 4-25 1664743-9 1991 The effect of 5 beta-pregnane-3,20-dione and progesterone was effectively blocked by RU486 but not by picrotoxin, suggesting that their actions were mediated through the progesterone receptor system. Mifepristone 85-90 progesterone receptor Rattus norvegicus 170-191 1839136-0 1991 Inhibition of the tocolytic activity of atrial natriuretic factor by progesterone and potentiation by progesterone receptor antagonist RU486 in rats. Mifepristone 135-140 progesterone receptor Rattus norvegicus 102-123 1995287-5 1991 When the antiprogestin [3H]RU486 was used instead of [3H]R5020 as a ligand, a 9 S PR was also found in the cytosol, but a nonactivated "8.5 S" receptor complex was identified in the high salt nuclear fraction in presence of tungstate ions. Mifepristone 27-32 progesterone receptor Rattus norvegicus 82-84 2263962-0 1990 [The comparison of the binding of Ru486 to progesterone receptor of pituitary and endometrium in ovariectomized rat]. Mifepristone 34-39 progesterone receptor Rattus norvegicus 43-64 2263962-2 1990 Thirty minutes after administration of Ru486 (2 mg/kg) the binding sites of progesterone receptor in both tissues showed a significant initial decrease, and then gradually reached the lowest level in 2 h. Afterwards the levels of progesterone receptor began to increase. Mifepristone 39-44 progesterone receptor Rattus norvegicus 76-97 2263962-2 1990 Thirty minutes after administration of Ru486 (2 mg/kg) the binding sites of progesterone receptor in both tissues showed a significant initial decrease, and then gradually reached the lowest level in 2 h. Afterwards the levels of progesterone receptor began to increase. Mifepristone 39-44 progesterone receptor Rattus norvegicus 230-251 2263962-3 1990 The results suggested that Ru486 could interact with progesterone receptor in both tissues. Mifepristone 27-32 progesterone receptor Rattus norvegicus 53-74 2263962-4 1990 However, the binding ability of Ru486 for different tissue was not exactly the same, and Ru486 binding to the progesterone receptor in endometrium might be easier. Mifepristone 89-94 progesterone receptor Rattus norvegicus 110-131 27389922-7 2016 Pretreatment with mifepristone, a progesterone receptor antagonist and hydroxyflutamid, an androgen receptor antagonist significantly diminished the neuroprotective effects of progesterone and testosterone, respectively. Mifepristone 18-30 progesterone receptor Rattus norvegicus 34-55 32618512-6 2020 At last, rats were intraperitoneally injected with progesterone receptor antagonist RU486, then the expression of eNOS and vasodilation function in thoracic aorta and mesenteric artery were measured. Mifepristone 84-89 progesterone receptor Rattus norvegicus 51-72 32618512-10 2020 We also observed that progesterone receptor antagonist RU486 reduced eNOS expression and impaired vasodilation in rats. Mifepristone 55-60 progesterone receptor Rattus norvegicus 22-43 28414589-8 2017 CONCLUSION: The blocking of progesterone receptor on these cells by mifepristone restored IDO expression levels and may constitute evidence of the participation of this hormone through a direct route in these cells. Mifepristone 68-80 progesterone receptor Rattus norvegicus 28-49 28387824-7 2017 Kp-10 also reduced dopamine levels in the ME of OVX+EP rats, an effect blocked by the progesterone receptor (PR) antagonist RU486. Mifepristone 124-129 progesterone receptor Rattus norvegicus 86-107 28387824-7 2017 Kp-10 also reduced dopamine levels in the ME of OVX+EP rats, an effect blocked by the progesterone receptor (PR) antagonist RU486. Mifepristone 124-129 progesterone receptor Rattus norvegicus 109-111 6627946-3 1983 RU-486 likely antagonizes progesterone action on the uterus progesterone receptor. Mifepristone 0-6 progesterone receptor Rattus norvegicus 60-81 6627946-8 1983 The relative abilities of the various tested steroids to bind to the rat ovary progesterone receptor were: RU-486 greater than or equal to R5020 greater than progesterone. Mifepristone 107-113 progesterone receptor Rattus norvegicus 79-100 33166560-4 2021 To assess the potential role of PR activity on the development of these connections and associated behavior, rats were treated daily from P1 to 7 with PR antagonist, RU486. Mifepristone 166-171 progesterone receptor Rattus norvegicus 151-153 33166560-5 2021 RU486 treatment increased the number of reelin-ir cells, suggesting an accumulation of reelin, implicating PR in the regulation of a principle developmental function of CR cells. Mifepristone 0-5 progesterone receptor Rattus norvegicus 107-109 33166560-6 2021 RU486 also altered the synaptic bouton marker, synaptophysin-ir, in a sex-specific manner, suggesting a role for PR activity in the development of perforant path innervation of the molecular layer (MOL). Mifepristone 0-5 progesterone receptor Rattus norvegicus 113-115 29127312-7 2017 Progesterone receptor antagonist RU-486 were further applied. Mifepristone 33-39 progesterone receptor Rattus norvegicus 0-21 29127312-11 2017 Moreover, progesterone receptor antagonist RU-486 partially reversed the effects of P4 on NF-kappaB pathway. Mifepristone 43-49 progesterone receptor Rattus norvegicus 10-31 28882474-7 2017 In a second study, gonadally intact dams were given the PR antagonist, RU 486, and were found to display more kyphosis and less supine nursing compared to controls. Mifepristone 71-77 progesterone receptor Rattus norvegicus 56-58 26165333-7 2015 As inhibitors of ER and PR activity, ICI 182,780 and mifepristone (RU486) were observed to reverse the E2 or 2-ME mediated increase of CaBP-9k and Ltf mRNA expression. Mifepristone 53-65 progesterone receptor Rattus norvegicus 24-26 26165333-7 2015 As inhibitors of ER and PR activity, ICI 182,780 and mifepristone (RU486) were observed to reverse the E2 or 2-ME mediated increase of CaBP-9k and Ltf mRNA expression. Mifepristone 67-72 progesterone receptor Rattus norvegicus 24-26 25152521-1 2014 RU486 is a partial progesterone and estrogen receptor antagonist, functioning to actively silence progesterone receptor gene-associated transcription. Mifepristone 0-5 progesterone receptor Rattus norvegicus 98-119 26004213-2 2015 To identify ovulatory specific PGR-regulated genes, a preliminary microarray analysis was performed using rat granulosa cells treated with hCG +- RU486 (PGR antagonist). Mifepristone 146-151 progesterone receptor Rattus norvegicus 31-34 26004213-2 2015 To identify ovulatory specific PGR-regulated genes, a preliminary microarray analysis was performed using rat granulosa cells treated with hCG +- RU486 (PGR antagonist). Mifepristone 146-151 progesterone receptor Rattus norvegicus 153-156 25972201-1 2015 It is well-known that indomethacin (the cyclooxygenase 1 & 2 inhibitor) and RU486 (or mifepristone, the progesterone receptor antagonist) block follicular rupture in rats. Mifepristone 90-102 progesterone receptor Rattus norvegicus 108-129 26190222-3 2015 RU486 was used to determine if a high dose and/or repeated treatment with EB enhanced proceptivity and reduced the response to mild stress through an intracellular progesterone receptor-mediated process. Mifepristone 0-5 progesterone receptor Rattus norvegicus 164-185 25152521-6 2014 Changes in the Pgr gene expression level as a consequence of RU486 administration was evaluated using quantitative real-time reverse transcription polymerase chain reaction. Mifepristone 61-66 progesterone receptor Rattus norvegicus 15-18 25152521-7 2014 The progesterone receptor gene and protein expression was ubiquitously decreased throughout pregnancy as a direct consequence of RU486 administration. Mifepristone 129-134 progesterone receptor Rattus norvegicus 4-25 23079166-5 2013 Mifepristone, a specific antagonist of progesterone receptor, abolished progesterone"s effect on body mass, inguinal fat mass, and lipogenic enzyme genes expression in inguinal adipose tissue. Mifepristone 0-12 progesterone receptor Rattus norvegicus 39-60 22634476-7 2012 RU 486, specific antagonist of progesterone receptor, abolished the effect of progesterone on the adipokine mRNA level in inguinal adipose tissue. Mifepristone 0-6 progesterone receptor Rattus norvegicus 31-52 23046854-3 2013 One hour before allopregnanolone, rats were injected with the progesterone receptor antagonist, RU486 (11beta-(4-dimethylamino)phenyl-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one), or vehicle. Mifepristone 96-101 progesterone receptor Rattus norvegicus 62-83 22116802-9 2012 Regulation of Mmp10 in cultured rat granulosa cells revealed that the EGF inhibitor AG1478 and the progesterone receptor antagonist RU486 suppressed the induction of Mmp10 mRNA, whereas the prostaglandin inhibitor NS398 had no effect. Mifepristone 132-137 progesterone receptor Rattus norvegicus 99-120 22326965-2 2012 Rats were treated with the PR antagonist mifepristone (daily oral gavage 40 mug/g/d) or vehicle between postnatal days 3 and 15. Mifepristone 41-53 progesterone receptor Rattus norvegicus 27-29 21945546-0 2011 Effects of RU486 in the expression of progesterone receptor isoforms in the hypothalamus and the preoptic area of the rat during postpartum estrus. Mifepristone 11-16 progesterone receptor Rattus norvegicus 38-59 21945546-3 2011 We studied the regulation of PR expression by its antagonist, RU486 in the hypothalamus and the preoptic area of the rat during postpartum estrus by Western blot. Mifepristone 62-67 progesterone receptor Rattus norvegicus 29-31 16934845-0 2006 Novel phosphorus-containing 17beta-side chain mifepristone analogues as progesterone receptor antagonists. Mifepristone 46-58 progesterone receptor Rattus norvegicus 72-93 21635894-15 2011 Finally, the progesterone receptor antagonist, RU486, attenuated progesterone"s protection against restraint. Mifepristone 47-52 progesterone receptor Rattus norvegicus 13-34 19450598-5 2009 Finally, we investigated the role of the high levels of progesterone typical of lactation in the suppression of estrogen-induced sexual behavior by transient blockade of the progesterone receptor using RU486. Mifepristone 202-207 progesterone receptor Rattus norvegicus 174-195 18001329-7 2007 In the progesterone-facilitation model, the LH response to GnRH injection was increased 2.5-3-fold (P < 0.05), an effect suppressed by the progesterone receptor antagonist, mifepristone. Mifepristone 176-188 progesterone receptor Rattus norvegicus 142-163 21440892-3 2011 The effect is blocked by pretreatment with progesterone receptor (PR) antagonist, RU486. Mifepristone 82-87 progesterone receptor Rattus norvegicus 43-64 21440892-3 2011 The effect is blocked by pretreatment with progesterone receptor (PR) antagonist, RU486. Mifepristone 82-87 progesterone receptor Rattus norvegicus 66-68 20950620-2 2011 Adult female rats were treated with the PR antagonist, RU486 (1.25 and 5 mg), 3 h after parturition and sexual behavior was evaluated throughout the first postpartum day. Mifepristone 55-60 progesterone receptor Rattus norvegicus 40-42 19389837-6 2009 To further explore Timp1 and Timp3 regulation, cells were cultured with the progesterone receptor antagonist RU486, which blocked the hCG induction of Timp3 expression, whereas the epidermal growth factor receptor tyrosine kinase inhibitor AG1478 blocked the hCG stimulation of both Timp1 and Timp3 expression. Mifepristone 109-114 progesterone receptor Rattus norvegicus 76-97 16934845-4 2006 Some of these compounds are more potent than mifepristone, with a better selectivity profile in differentiating progesterone receptor from glucocorticoid receptor. Mifepristone 45-57 progesterone receptor Rattus norvegicus 112-133 16825604-9 2006 Treatment with RU486, a progesterone receptor (PR) antagonist, completely blocked P4-induced CaT1 mRNA, indicating that P4 regulates CaT1 mRNA expression via a PR-mediated pathway. Mifepristone 15-20 progesterone receptor Rattus norvegicus 24-45 16825604-9 2006 Treatment with RU486, a progesterone receptor (PR) antagonist, completely blocked P4-induced CaT1 mRNA, indicating that P4 regulates CaT1 mRNA expression via a PR-mediated pathway. Mifepristone 15-20 progesterone receptor Rattus norvegicus 47-49 16825604-9 2006 Treatment with RU486, a progesterone receptor (PR) antagonist, completely blocked P4-induced CaT1 mRNA, indicating that P4 regulates CaT1 mRNA expression via a PR-mediated pathway. Mifepristone 15-20 progesterone receptor Rattus norvegicus 160-162 12080023-7 2002 In contrast, administration of the progesterone receptor antagonist RU486 (10 mg/kg s.c.) on Day 19 induced preterm labor and a premature increase in mRNA levels of c-fos, fra-1, fra-2, and junB. Mifepristone 68-73 progesterone receptor Rattus norvegicus 35-56 16818706-8 2006 RU-486 delayed the latency period and decreased tumor incidence in animals exposed to MPA at 4 weeks after DMBA treatment, indicating that the progesterone receptor may be partially responsible for transmission of proliferative signals. Mifepristone 0-6 progesterone receptor Rattus norvegicus 143-164 16233985-3 2006 The stimulatory action of progesterone on nitric oxide synthase (NOS) activity was maintained even in the presence of an antagonist of progesterone receptor, compound RU486. Mifepristone 167-172 progesterone receptor Rattus norvegicus 135-156 14645109-8 2004 Treatment of pregnant rats with the progesterone receptor antagonist RU486 on Day 19 induced preterm labor on Day 20 and a premature increase in mRNA levels of collagen IV, fibronectin, and laminin. Mifepristone 69-74 progesterone receptor Rattus norvegicus 36-57 12388156-10 2002 RU-486 caused early parturition associated with increased PR-total mRNA, with no change in PR-B. Mifepristone 0-6 progesterone receptor Rattus norvegicus 58-60 12457039-3 2002 To test this hypothesis, the progesterone receptor antagonist, RU486, was administered to regularly cycling proestrous rats and the effect on GAD(67) and GAD(65) mRNA levels in the preoptic area (POA) and medial basal hypothalamus (MBH) was examined. Mifepristone 63-68 progesterone receptor Rattus norvegicus 29-50 11958787-3 2002 The highest affinity of PR to DNA (equilibrium K(a) = 0.420 +/- 0.185 nM(-1)) was found in the presence of the partial agonist/antagonist RU486, while the lowest affinity (K(a) = 0.074 +/- 0.013 nM(-1)) was demonstrated with the full agonist 6alpha-methyl-16alpha,17alpha-cyclohexanoprogesterone. Mifepristone 138-143 progesterone receptor Rattus norvegicus 24-26 8853395-1 1996 Previous studies have demonstrated antiglucocorticoid actions for the progesterone receptor antagonist RU-486. Mifepristone 103-109 progesterone receptor Rattus norvegicus 70-91 11058452-9 2000 RU486, a progesterone receptor antagonist, enhanced supraoptic neurone Fos expression in late pregnancy, indicating progesterone receptor-mediated actions. Mifepristone 0-5 progesterone receptor Rattus norvegicus 9-30 11058452-9 2000 RU486, a progesterone receptor antagonist, enhanced supraoptic neurone Fos expression in late pregnancy, indicating progesterone receptor-mediated actions. Mifepristone 0-5 progesterone receptor Rattus norvegicus 116-137 10048465-12 1999 RU486, a progesterone receptor antagonist, was used to assess whether the stimulatory effects of cGMP are mediated through the progesterone receptor. Mifepristone 0-5 progesterone receptor Rattus norvegicus 9-30 11369298-5 2001 Correlation among the mRNA expression levels of PACAP, dPRP and the progesterone receptor and the coordinated inhibitory actions of the anti-progesterone (RU-486) suggest that there is also correlated time-dependent steroid regulation of the mRNA levels of PACAP, dPRP and the progesterone receptor in the decidual and pregnant uteri. Mifepristone 155-161 progesterone receptor Rattus norvegicus 68-89 11369298-5 2001 Correlation among the mRNA expression levels of PACAP, dPRP and the progesterone receptor and the coordinated inhibitory actions of the anti-progesterone (RU-486) suggest that there is also correlated time-dependent steroid regulation of the mRNA levels of PACAP, dPRP and the progesterone receptor in the decidual and pregnant uteri. Mifepristone 155-161 progesterone receptor Rattus norvegicus 277-298 10965915-8 2000 RU486 completely blocked progesterone-induced PR down-regulation. Mifepristone 0-5 progesterone receptor Rattus norvegicus 46-48 9870258-6 1998 The physiological role of progresterone in the induction of the preovulatory gonadotropin surge has been demonstrated by the attenuation of the progesterone-induced surge and the endogenous proestrus surge by progesterone receptor antagonist RU486 and the progesterone synthesis inhibitor trilostane. Mifepristone 242-247 progesterone receptor Rattus norvegicus 209-230 9780328-6 1998 Furthermore, blocking progesterone actions with progesterone receptor antagonists RU-486 or ZK98299 without affecting PRL secretion inhibited apoptosis but did not affect the accumulation of macrophages, whether treatment was started on the morning of metestrus (blocking diestrous and proestrous progesterone) or on proestrus (blocking only proestrous progesterone). Mifepristone 82-88 progesterone receptor Rattus norvegicus 48-69 9603245-2 1998 These actions are steroid specific and dose dependent and are inhibited by the progesterone receptor (PR) antagonist, RU-486. Mifepristone 118-124 progesterone receptor Rattus norvegicus 79-100 9603245-2 1998 These actions are steroid specific and dose dependent and are inhibited by the progesterone receptor (PR) antagonist, RU-486. Mifepristone 118-124 progesterone receptor Rattus norvegicus 102-104 9165013-1 1997 Previous in vivo studies from our laboratory indicated that administration of the antiprogestin RU486 on proestrus suppresses both the preovulatory gonadotropin surges and the secondary FSH surge, suggesting a role for the progesterone receptor (PR) in the generation of these surges. Mifepristone 96-101 progesterone receptor Rattus norvegicus 223-244 9165013-1 1997 Previous in vivo studies from our laboratory indicated that administration of the antiprogestin RU486 on proestrus suppresses both the preovulatory gonadotropin surges and the secondary FSH surge, suggesting a role for the progesterone receptor (PR) in the generation of these surges. Mifepristone 96-101 progesterone receptor Rattus norvegicus 246-248 8243259-4 1993 On proestrus, hourly blood samples were collected from 1100-2100 h. At 1230 h, rats received a sc injection of the progesterone receptor antagonist RU486 (6 mg/kg BW) or oil. Mifepristone 148-153 progesterone receptor Rattus norvegicus 115-136 8243259-12 1993 Our results demonstrate that 1) NPY facilitates LHRH-induced LH surges on the afternoon of proestrus; 2) presumptive progesterone receptor blockade by RU486 completely prevents NPY"s potentiating effects; and 3) NPY is without effect on the morning of proestrus, before the afternoon surge of progesterone. Mifepristone 151-156 progesterone receptor Rattus norvegicus 117-138 8169558-5 1994 The cell-specific distribution of these proteins was determined in the rat uterus during early pregnancy and after injection of the progesterone receptor antagonist mifepristone (RU 486) at days 1 and 2 post coitum (p.c.) Mifepristone 165-177 progesterone receptor Rattus norvegicus 132-153 7693394-1 1993 The antigestagen mifepristone (RU 486) acts by blocking the progesterone receptor. Mifepristone 17-29 progesterone receptor Rattus norvegicus 60-81 8245220-11 1993 (7) Treatment of intact rats with the progesterone receptor antagonist, RU 486, during the proestrus phase of the estrous cycle inhibits the proestrus to estrus drop in spine density. Mifepristone 72-78 progesterone receptor Rattus norvegicus 38-59 7693394-1 1993 The antigestagen mifepristone (RU 486) acts by blocking the progesterone receptor. Mifepristone 31-37 progesterone receptor Rattus norvegicus 60-81